CLSN - H.C. Wainwright initiates coverage on Celsion with a buy rating on promising DNA-based COVID-19 vaccine program

Celsion Corporation (NASDAQ:CLSN +11.5%) stock jumps after H.C. Wainwright analyst Emily Bodnar initiates coverage on the stock with a Buy rating and a price target of $16, implies a 360% increase from last price. The company is developing its novel DNA-based platforms, TheraPlas and PLACCINE, which are entirely different from the ThermoDox technology which involved heat-activated chemotherapeutic agents and was discontinued in 2021. The company has initiated a non-human primate (NHP) study and a mouse-challenge study for its novel DNA-based COVID-19 vaccine candidates, results of which are expected in 2Q22 and 3Q22 an if data are positive, the company will seek a partner to take the program into the clinic. CLSN shares have slipped more than 57% since the start of 2022 and is currently trading near to its 52-week low levels.

For further details see:

H.C. Wainwright initiates coverage on Celsion with a buy rating on promising DNA-based COVID-19 vaccine program